The development of transcriptionally controlled systems which function in eukaryotic cells are important for achieving regulated gene expression in gene therapy. In this study we combined the components of the tetracycline-inducible system in self-contained retroviral and plasmid vectors. Regulated reporter gene expression from the autoregulatory plasmid pGTRTL in response to doxycycline (Dox) induction surpasses the expression observed from other self-contained retroviral and plasmid vectors. Induction kinetics and expression levels of luciferase and the therapeutic molecule, truncated soluble complement receptor 1 (sCR1) were characterised in a mouse fibroblast and a human neuroblastoma cell line. The regulatory characteristics of the plasmids
Introduction
Regulating expression of therapeutic genes is a prerequisite to the clinical application of gene therapy to the treatment of chronic conditions with relapsing symptoms, such as rheumatoid arthritis and multiple sclerosis. Restricting expression of therapeutics in these conditions to periods when relapses occur will prevent potential side-effects from long-term expression of therapeutic proteins.
The tetracycline system for regulated gene expression was originally developed as a two vector 'off' system in which a chimeric tetracycline transactivator (tTA), composed of tetR and VP16 is constitutively expressed from one vector, and binds to a tetracycline operon (tetO) containing promoter in a second vector inducing gene expression. 1 When tetracycline is added it binds tTA and induces a conformational change which prevents it from binding to the tetO and thus switches off gene expression. The 'off' system displays regulated expression in excess of 1000-fold when the two vectors are stably transfected into HeLa cells. Several studies were shown to be optimal for gene therapy applications, as there was a rapid reduction in expression levels following removal of Dox. Co-transfection of cells with an autoregulatory plasmid and a Dox inducible enhanced green fluorescent protein (EGFP) plasmid demonstrated the feasibility of using this plasmid combination to achieve parallel regulation of two genes of interest in a single cell under the control of Dox. These novel autoregulatory plasmids display the requirements for gene therapy applications in chronic conditions which are remitting/relapsing such as rheumatoid arthritis or multiple sclerosis, where novel protein therapeutics and combination therapies are needed. Gene Therapy (2000) 7, 2061-2070.
have since reported adaptations of the original tetracycline 'off' system which facilitate application in gene therapy settings. One variation involves combining the components of the two vectors in a single self-contained vector, which avoids the need to deliver two vectors to a single cell, this combination has been reported with both retroviral 2, 3 and plasmid vectors. 4 Another modification has been expressing tTA under the control of a tetO promoter. In this autoregulatory format the tTA regulates its own expression, in the absence of tetracycline the tTA is able to interact with the tetO promoter and can therefore up-regulate its own expression in a positive feedback loop. When tetracycline is added to the system the tTA can no longer interact with the promoter and so tTA expression is down-regulated. The advantage of autoregulated expression of tTA is low level expression of tTA in the presence of tetracycline, which should reduce toxic effects of constitutively expressed tTA, and higher levels of inducible gene expression when tetracycline is removed. This autoregulation has been adopted in both two vectors 5 and self-contained vectors. 4, 6 Gossen and co-workers 7 later developed a two-vector tetracycline 'on' system. Mutation of the tTA produced the reverse tetracycline transactivator (rtTA) which induces gene expression in the presence of doxycycline (Dox). 7 Modifications of the 'on' system include the construction of a self-contained single bacterial plasmid, 8 a retroviral vector 9 and an autoregulatory bicistronic plas-mid 10 all of which were reported during the course of our research. In this study we compare the regulatory response of the 'on system' when the components are combined in self-contained retroviral or plasmid vectors in a standard or autoregulatory format. The kinetics of gene induction for an autoregulatory plasmid are fully characterised and its application in the regulation of two genes from a single cell examined.
Results
Comparative induction characteristics of retroviral and plasmid vectors We have constructed in parallel self-contained retroviral and plasmid vectors (Figure 1 ). The backbone for the retroviral vector was MFG which is the highest expressing vector of the Moloney retroviral vectors. 11 Plasmids were constructed on the backbone of the pGL2 basic vector which is devoid of promoter and enhancer elements, that could interfere with gene transcription and Dox regulation. In addition the plasmid contains polyadenyl- ation (poly A) signals that are beneficial for the study of gene regulation. One SV40 early poly A is positioned upstream of luciferase to reduce cryptic transcription which may have initiated within the vector ensuring that basal gene expression from the vector is minimal. A second SV40 poly A located between luciferase and the rtTA acts as the termination signal for both genes, in a context similar to the location within the wild-type SV40 virus, where it functions as an efficient bi-directional terminator of RNA transcription. 12 Preliminary transfection studies confirmed that DBA tst fibroblasts (DTF) are a suitable cell line for the study of tetracycline inducible expression. Co-transfection of pUHC 13-3 and pUHG 17-1 in a ratio between 1:10 and 1:1 was optimal for Dox-regulated luciferase expression from DTF by transient transfection (data not shown).
Comparative induction of luciferase from retroviral (M1-LUC CMV and M2-LUC CMV) and plasmid constructs (pGRTL and pGTRTL) was performed by transient transfection of DTF. Following induction with Dox for 48 h the degree of gene induction was 23-, 21-, 12-and 34-fold, respectively ( Figure 2 ). In terms of the induced level of luciferase expression the ranked order for these vectors is pGTRTL Ͼ M2-LUC CMV Ͼ M1-LUC CMV у pGRTL. For a quantitative analysis of the level of luciferase expression, these vectors were compared with the constitutive cytomegalovirus immediate/early (CMV) promoter in the construct pGCMV by transient transfection of DTF with equivalent amounts of each vector. After 24 h induction with Dox, luciferase expression from pGTRTL was equivalent to 25% of the CMV promoter while expression from pGRTL was less than 1% (Table 1) .
In view of the higher degree of gene induction and level of gene expression from pGTRTL further analysis was focused on this autoregulatory plasmid. Comparison of basal and induced luciferase expression from GTRTL to expression from pGTL and pGCMV The basal activity of the seven repeats of the tetO located upstream from a minimal CMV promoter (tetP) in DTF was assessed by comparison of luciferase expression following transient transfection with pGTL and pGL2 basic. Luciferase expression was significantly higher (P Ͻ 0.005) from the tetP containing plasmid pGTL compared with the promoterless vector pGL2 basic ( Figure 3a) . The basal level of luciferase expression from pGTRTL was also compared with pGTL, both plasmids are identical except for the inclusion of the tetP-rtTA cassette in pGTRTL. Results in Figure 3a illustrate that in the absence of Dox, luciferase expression from pGTRTL was 119.9 RLU compared with 55.23 RLU for pGTL, indicating a slight but significant (P Ͻ 0.05) increase in promoter activity by inclusion of the tetP-rtTA cassette in pGTRTL.
Comparison of luciferase expression from pGTRTL (induced with Dox) and pGCMV over a period of 48 h revealed that luciferase expression, as a percentage of CMV driven expression, increased to 4%, 38%, and 81% at intervals of 6, 24 and 48 hours (Figure 3b ). Basal expression of luciferase from pGTRTL was in the region of 2-3% of the constitutive CMV promoter throughout the 48-h time-course.
Regulated expression in other cell types
To confirm that regulated expression from pGTRTL can also be achieved in cells from other species we have used the human neuroblastoma cell line NB100. Twelve stable clones were obtained for pGRTL, of these only one was responsive to Dox induction, and again the level of luciferase expression observed was low (not shown). Retroviral constructs M1-LUC CMV and M2-LUC CMV were stably transfected in to the GP+E86 packaging cells by co-transfection with the selection plasmid pSV2Neo. No stable clones were obtained for M1-LUC CMV, and the best stable clone for M2-LUC CMV displayed Dox-regulated expression of luciferase up to 25-fold (not shown).
Kinetics of luciferase regulation from a stable clone
The highest degree of luciferase regulation was observed with DTF GTRTL clone 21, which displayed an increase of 62-fold after 72 h Dox induction (Figure 5b ). DTF-GTRTL clone 10 was used as a representative clone to examine the 'on'/'off' kinetics of luciferase expression at time-points of 24, 48 and 72 h after switching maximally induced cells (induced with Dox for 96 h) to Dox-free media, and non-induced cells to Dox-containing media. Luciferase expression was shown to be rapidly up-and down-regulated following the addition or removal of Dox, respectively. Expression of luciferase in induced cells started to plateau after 48 h ( Figure 5c ) whilst expression was rapidly switched 'off' following removal of Dox reaching 8% above baseline after 48 h (Figure 5c ).
Stable transfectants with GTRTC
Stable DTF clones expressing truncated soluble complement receptor 1 (sCR1) were obtained after transfection with pGTRTC (20 g) with pTKHyg (1 g) and selected in hygromycin B containing medium. Thirty-one clones were tested for inducible Dox expression of sCR1, of these 30 demonstrated inducible sCR1 expression detected by Western blot after 24 h induction (not shown). A selection of these clones were induced with Dox for 48 h and sCR1 expression determined by ELISA (Figure 6a ). Induction of sCR1 was significant for four of these clones. As with stable pGTRTL clones a range of induction and expression levels were observed with clone 2 displaying the greatest degree of induction at 74-fold and clone 4 achieving the highest induced level of expression. 'On'/'off' regulation of sCR1 expression from a stable DTF GTRTC clone 'On' and 'off' kinetics of sCR1 expression was examined in DTF GTRTC clone 1 at 24-h intervals over a 72-h time course. Before examining the 'on'/'off' kinetics of sCR1 expression, non-induced cells were maintained in Dox-free media, and induced cells were grown in Dox (1 g/ml) containing medium for 96 h. Induction of sCR1 expression was assessed as the expression of sCR1 in a 24-h period following Dox induction of non-induced cells. The switching 'off' of sCR1 expression was determined as the level of sCR1 expression in a 24-h period after switching induced cells to Dox-free media. Levels of sCR1 were significantly increased by Dox induction at 24 and 48 h compared with non-induced levels, with expression after 48 h equivalent to continuously induced cells. The degree of sCR1 induction was 10-, 42-and 54.5-fold at 24, 48 and 72 h, respectively (Figure 6b (Figure 6b ). There is a background increase in sCR1 expression for all groups due to the increase in cell numbers over the course of the experiment.
Dual regulation of sCR1 and enhanced green fluorescent protein in a single cell Regulated expression of both sCR1 and enhanced green fluorescent protein (EGFP) was examined in DTF clones obtained after co-transfection with pGTRTC (10 g), pGTE (10 g) and pTKHyg (1 g) and selection for hygromycin B resistance. The use of an inducible GTE construct in this transfection acts as a marker for clones containing pGTRTC as Dox induction of EGFP is dependent upon rtTA expression from the autoregulatory plasmid pGTRTC. Eight clones were induced with Dox for 48 h. After induction five clones were observed to express EGFP and sCR1, whilst the remaining three clones expressed neither protein (data not shown). These result confirm that an inducible EGFP plasmid can be used as an accurate marker of a functional autoregulatory vector.
Expression of sCR1 and EGFP from clone 21 was monitored at time-points of 24, 48 and 72 h after induction with Dox. Expression of sCR1 measured by ELISA, showed significant increase over the course of the experiment to give a maximum induction of 51-fold after 72 h (Figure 7a) . Expression of EGFP in the same cells was measured by flow cytometry and also showed similar kinetics of expression with a maximum induction of 16-fold observed after 72 h (Figure 7b ). The parallel expression of sCR1 and EGFP in these cells shows good correlation over the 72-h time course with a correlation coefficient of r = 0.837.
Discussion
The successful application of gene therapy in the treatment of diseases which are remitting/relapsing in nature is dependent upon the implementation of effective systems to regulate expression of therapeutic genes. The tetracycline regulatory system is particularly suited to application for these clinical conditions. Inducer molecules for this system such as tetracycline have welldefined pharmacology and in addition these compounds may have beneficial effects as in arthritis where they inhibit MMP action, 13, 14 increase iNOS mRNA degradation 15 and enhance calcium flux in activated T cells. 16 Regulated expression of luciferase assessed by transient transfection indicated that both the degree of regulation and the induced level of luciferase expression were markedly lower from the self-contained retroviral vectors M1-LUC CMV, M2-LUC CMV and the plasmid pGRTL, compared with the enhancerless autoregulatory self-contained plasmid pGTRTL. Expression of rtTA from these three vectors is driven by a CMV promoter, whereas a tetP is utilised in pGTRTL. This difference indicates that the CMV in some way compromises the regulatory capacity of the tetP driving expression of luciferase.
Enhancers are able to bind to promoter regions situated several thousands of bases away through DNA folding. 17 A similar interaction between the enhancer elements of the CMV and the minimal CMV (mCMV) of the tetP may occur in these self-contained vectors. In the event of such an interaction, rtTA may be prevented from binding to the tetO elements of the tetP, or the expression of rtTA from the adjacent CMV promoter may in some way be reduced. The vectors M2-LUC CMV and pGRTL are strictly identical with the exception of the retroviral backbone and LTRs. Interestingly, despite the close structural similarity the induced expression of luciferase after 24 h induction was considerably different at 7.69% and 0.87% relative to expression from a CMV promoter.
M1-LUC CMV is unique compared with the other vectors constructed in that the promoter elements of the LTR, CMV and the tetP are all orientated in the same direction. In theory this could produce additive promoter activity resulting in expression of rtTA at toxic levels, and may explain the impossibility to obtain stable clones with this construct. In the other constructs the opposing promoters may give rise to antisense mRNA which might maintain rtTA expression below toxic levels.
There are four important criteria that need to be ascertained in order to fully characterise regulatable vectors. The basal non-induced level of gene expression; the maximal level of gene expression achieved in the induced state; the degree of regulation observed upon induction; and finally the kinetics of switching gene expression 'on' and 'off'. We have addressed the first two criteria by transient transfection experiments whilst the other parameters were assessed in permanent transfectants.
The strength of the induced promoter activity in pGTRTL was shown to approach that of a constitutive CMV IE promoter which is the strongest known constitutive promoter in most eukaryotic cells. These observations confirm that good expression levels are achieved with pGTRTL, although the strength of the tetP may be lower in the context of autoregulatory plasmid when compared with observations made with the two plasmid 'off' system. Expression of luciferase from pGTL provides a measure of the innate promoter activity of the tetP. We have shown that the tetP displays significant promoter activity by comparison to the promoterless plasmid pGL2 basic. The basal activity of tetP has previously been shown to be dependent upon the cell type in which it is employed, with high basal expression of genes observed in several cell lines. 18 The embryonic mouse fibroblast NIH 3T3 19 is one of the cell lines in which high basal activity of tetP is observed. DTF are also primary embryonic fibroblasts but from DBA/1 mice and are conditionally immortalised with the temperature-sensitive large T antigen of SV40 as previously described, 20 and this similarity suggests that the high basal activity of tetP observed in this study is a consequence of the cells employed.
The degree of regulated luciferase expression from pGTRTL was in the order of 30-fold in transiently transfected cells. Upon stable integration of pGTRTL, regulation of luciferase expression was in excess of 60-fold for the highest expressing clones. In addition we have been able to extend these observations to a therapeutic gene, sCR1 which is a potent inhibitor of the complement cascade 21 with proven effect by gene therapy in a mouse arthritis model. 22 Regulated expression of sCR1 from per-manent transfectants with the construct GTRTC displayed maximal regulation in excess of 70-fold. The improved regulation observed with permanent transfectants probably occurs via favourable interactions with DNA sequences adjacent to the site of integration which reduce basal expression and enable good induction of gene expression. The regulation we have observed in DTF is similar to the 80-fold induction of luciferase reported for a commercially available NIH 3T3 cell line (Clontech) permanently integrated with the tTA and transiently transfected with a tet-inducible luciferase construct. The degree of regulation that we have observed using a reporter and therapeutic gene is similar to other self-contained 'on' vectors. In addition transient transfection of NB100 cells confirms that these vectors function in human cells which are the ultimate target for the therapeutic application of gene therapy. The 'on'/'off' kinetics of gene expression was examined in stable DTF transfectants of GTRTL and GTRTC. In both cases gene expression reached or approached a maximum after 48 h induction with Dox, and where Dox was removed from maximally induced cells expression approached or returned to baseline by 48 h. The single change of medium in the luciferase kinetics experiment probably accounts for the fact that expression neither reached maximal nor basal levels following addition and removal of Dox. A residual amount of Dox in the media would prevent the complete switch 'off' occurring, and restimulation of maximally induced cells after 96 h may have boosted the level of expression slightly above that feasible with a single induction. In general the kinetics of induction for these clones is slightly slower than reported for the permanently integrated two plasmid 'on' system where maximal expression is achieved in less than 24 h. 7 The slower induction observed with our plasmids is probably explained by the autoregulated expression of rtTA resulting in a delay in optimal levels of rtTA expression. No previous in vitro data have been published on the kinetics of switching 'off' expression using the 'on' system, but our findings with these autoregulatory plasmids is comparable to observations in vivo with the two plasmid 'on' system 23 and demonstrates their suitability to gene therapy applications. Kinetics of gene regulation in the 'off' system has been reported for a selfcontained plasmid pSiaII, where Dox was shown to switch 'off' GM-CSF expression after 24 h, but following removal of Dox for 150 h the reversal in GM-CSF expression was only 50%, and maximal gene expression was only observed after more than 9 days. 24 Intriguingly an autoregulated plasmid pSiaIV produced by the same group only displayed 30% return to maximal expression 9 days after removal of Dox. 4 The optimal 'on'/'off' kinetics of gene expression displayed by our autoregulatory plasmids may be explained by their novel design. To our knowledge this is the first autoregulatory plasmid incorporating two tetP promoters in close proximity in sense and anti-sense orientations and both utilising the same bidirectional SV40 poly A. The direct opposition of the two regulatable promoters may facilitate their own down-regulation as rtTA levels are reduced through autoregulation following Dox removal.
The autoregulated expression of tTA was first adopted in a two vector system 5 and was later incorporated into self-contained vectors. 4, 6 In the 'off' system tTA autoGene Therapy regulation results in high level expression of tTA in the absence of antibiotic. However, it has been postulated that tTA may have a 'squelching' effect at high intracellular levels. 1 Indeed this view was supported by a study which indicates that continued high level tTA expression from an autoregulatory vector is detrimental to cell functions including growth and cell cycle. 25 By contrast cells maintained in the presence of tetracycline displayed normal growth characteristics. The toxic effects of tTA are usually attributed to the potential 'squelching' effect of the VP16 component, but the tetR component could also contribute as toxic effects have been demonstrated in plants. 26 It appears that autoregulated expression of tTa in the 'off' system has been inappropriately applied, and perhaps the application of autoregulatory expression of the 'on' system is more appropriate. Autoregulated expression of rtTA in the 'on' system results in low basal levels of rtTA expression in the absence of Dox, and induction with Dox leads to increased levels of rtTA through positive feedback. In this scenario high levels of rtTA are only produced when gene expression is induced with Dox. Therefore, gene therapy applications using this type of construct, where short-term gene induction is required, will ensure that cells are only exposed to high levels of rtTA for a short period of time. In addition the rapid kinetics of the switch 'off' observed in this study indicate that cells will not be exposed to high levels of rtTA for prolonged periods of time following removal of Dox.
In an endeavour to expand the potential application of these novel plasmids further we examined the regulation of two genes in different plasmids from a single cell. When DTF were co-transfected with the autoregulatory plasmid pGTRTC, and the inducible plasmid pGTE we were able to detect Dox inducible EGFP expression in clones bearing the GTRTC plasmid. The regulation of sCR1 expression was of a similar magnitude observed with clones transfected with GTRTC alone. The expression of EGFP and sCR1 was shown to correlate over a time course up to 72 h for one clone examined. These findings indicate that selection of clones on the basis of their EGFP expression profile is a viable shortcut in the selection of clones which display optimal regulatory expression of a gene of interest (GOI). Monitoring EGFP expression would be advantageous where rapid methods are not available to monitor expression of the GOI efficiently. Where cells are intended for in vivo applications the stable incorporation of pGTE may prove detrimental due to immune rejection of EGFP expressing cells, 27 however it would still be possible to transiently transfect pGTE in stable clones with an autoregulatory plasmid in order to confirm integration of the autoregulatory plasmid and in order to characterise the regulation of a GOI.
Finally, co-regulating the expression of two therapeutic genes could be achieved by co-transfection of an autoregulatory and an inducible plasmid each containing a therapeutic gene. Co-regulated expression of two therapeutic genes has wide potential application in many therapeutic situations, but will be of optimum benefit where the gene products have additive or synergistic therapeutic effect. The advantage of this co-transfection approach, over the use of a bicistronic mRNA expressed from an inducible promoter, 28 is that varying the ratio of the two plasmids during transfection will alter the proportion of the two gene products upon induction, rather than the fixed ratio that results from bicistronic mRNA. In addition co-transfection can be used to rapidly assess the therapeutic effect of several gene combinations without the need to clone gene combinations physically in a bicistronic construct.
Materials and methods
Cells DTF are primary DBA/1 embryonic fibroblasts immortalised with the temperature sensitive SV40 large T antigen and were grown in DMEM supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 g/ml) and 2 mm glutamine as previously described. 20 The retroviral packaging cell line GP+E86 was maintained DMEM with newborn calf serum and the human neuroblastoma cell line NB100 20 were grown in DMEM supplemented with 10% FCS.
Cloning strategy
The plasmids pUHG17-1, pUHD10-3 and pUHC13-3 7 were generously provided by Gossen and Bujard (Universitat Heidelberg, Germany).
Retroviral constructs were based on a previously described mini MFG murine Moloney retroviral vector. 29 The CMV-rtTA cassette was removed from pUHG17-1 as an XhoI-blunt-BamHI fragment and cloned into mini-MFG restricted with BstXI-blunt-BamHI resulting in the vector MFGCMVrtTA. The tetP was removed from pUHD10-3 by XhoI-EcoRI digest, blunted and subcloned into pBluescript II KS (Stratagene, La Jolla, CA, USA) which had been restricted with Asp718-XhoI and also blunted with Klenow, producing the vector pBStet. The tetP cassette with the downstream multiple cloning site (MCS) was removed from pBStet by restriction with XhoI-XbaI, blunted and ligated with BglII linkers, restricted with BglII and cloned into MFGCMVrtTA cut with BamHI. Two vectors were obtained, MGTT-1 and MGTT-2 in which the tetP is located downstream of the rtTA in the sense and anti-sense direction, respectively. Luciferase was cloned into MGTT-1 and MGTT-2 from pGL2 basic (Promega, Madison, WI, USA). Luciferase along with a downstream SV40 untranslated region and poly A were removed from pGL2 basic by restriction with BamHI and BglII, and cloned into the retroviral vectors linearised with BamHI, the resulting vectors were called M1-LUC CMV and M2-LUC CMV (Figure 1) .
The self-contained inducible plasmids and intermediary subclones were all constructed on the pGL2 basic backbone. The restriction site BbsI in the mCMV is common to both the full-length CMV and the tetP promoter and was utilised in constructing the autoregulatory rtTA unit. The plasmid pUHC13-3 was restricted with XhoI and BbsI and the released fragment was inserted upstream of rtTA in pUHG17-1 cut XhoI-BbsI, creating plasmid pRT. The CMV-rtTA and tetP-rtTA cassettes were removed by restriction with XhoI-BamHI from pUHG17-1 and pRT, respectively, and inserted in the 3Ј-5Ј orientation in the SalI-BamHI sites of pGL2 basic, the resulting vectors were named pGR and pGTR. The plasmid pUHC13-3 was subsequently cut 5Ј of the tetP with XhoI and towards the 3Ј terminus of luciferase with ClaI.
This cassette was cloned into both pGR and pGTR cut XhoI-ClaI, thus reconstituting the full-length luciferase gene. The constructs obtained were termed pGRTL and pGTRTL respectively (Figure 1) .
The inducible luciferase plasmid pGTL equivalent to pUHC13-3 but on the pGL2 backbone was constructed by restricting pGL2 basic with XhoI-ClaI, and ligating in the tetP-luciferase cassette cut with the same enzymes from pUHC 13-3. The plasmid pGT with a tetP upstream from an MCS on the pGL2 basic backbone is equivalent to pUHC 10-3 and was cloned by removing the tetP-MCS cassette from pBStet with BstXI-blunted-XhoI and inserting it into pGTL with the tetP-luciferase cassette removed by restriction with XhoI-EcoRV. An inducible vector pGTE expressing EGFP was also constructed by removal of the EGFP gene from pEGFP-1 (Clontech, Palo Alto, CA, USA) by EcoRI-NotI restriction and inserted into pGT cut with the same enzymes (Figure 1) .
We have previously constructed a retroviral vector MFG-CR1, which expresses a truncated form of sCR1. 22 The sCR1 gene was removed from this vector by the restriction NcoI-blunted-NotI, and cloned into the pGT vector cut with EcoRV-NotI, forming the inducible vector pGTC1. The autoregulatory vector expressing sCR1 required transfer of the tetP-sCR1 cassette (restricted NheI-BspMI) from pGTC1 and cloned into pGTRTL cut with the same enzymes, producing the autoregulatory vector pGTRTC (Figure 1) .
A control plasmid from which luciferase was constitutively expressed from an CMV promoter was also constructed by removing the CMV promoter from pcDNA3 (Invitrogen, Leek, The Netherlands) by restriction with NruI and XhoI and inserted into the MCS of pGL2 basic restricted SmaI-XhoI creating the plasmid pGCMV ( Figure 1 ).
Preparation of DNA
Large-scale preparation of DNA was performed by the standard caesium chloride method. 30 Purified DNA was resuspended in sterilised distilled water and the DNA concentration was determined by absorbance measurement at 260 nm.
Transient transfection DTF or NB100 cells were seeded in six-well plates at 0.25-0.5 × 10 6 cells per well and transfected with DNA the next day using the calcium phosphate co-precipitation method. 31 For accurate comparison of plasmids, transfections were performed with molar equivalents of DNA. Following transfection, cells were cultured in 3 ml medium with or without Dox (1 g/ml). Experiments were terminated between 6 and 72 h later when luciferase expression was determined in the cell lysate.
Permanent transfection
Cells for transfection were seeded on 9 cm plates at 0.5 × 10 6 cells per plate. The next day cells were co-transfected with either an inducible retroviral vector (20 g ) and the selection construct pSV2Neo (1 g) 32 or an inducible plasmid vector (20 g ) and the selection construct pTK-Hyg (Clontech) (1 g). Inducible plasmid vectors were either transfected in isolation as 20 g of a single autoregulatory vector (ie pGTRTL) or as a combination with 10 g each of an autoregulatory and inducible vector (ie pGTRTC and pGTE). The DNA was precipitated as above and cells treated with 10% glycerol. The next day cells were split 1 to 5 and cultured overnight before selection was initiated by growth in medium supplemented with the respective selection antibiotic, G418 (1 mg/ml) (Life Technologies, Paisley, UK) or hygromycin B (200 g/ml) (Calbiochem-Novabiochem, La Jolla, CA, USA). The selection medium was changed twice weekly and single clones were visible after 3 weeks. Clones were isolated by washing plates with PBS and placing discs of autoclaved 3MM paper soaked in trypsin/EDTA over visible clones. Plates were returned to the incubator for 4 min after which the paper was transferred to individual wells in 12-well plates containing 1 ml Hygromycin selection medium. Clones were grown until approximately 70% confluence before examining Dox inducible expression of sCR1, or were split to triplicate wells for examination of luciferase expression. Kinetics of gene regulation of stable clones were performed by plating cells in six-or 12-well plates at 1 × 
Measurement of sCR1 by ELISA
The direct measurement of sCR1 in culture media by ELISA was performed as previously described. 22 ELISA plates were coated overnight with anti-CR1 mAb J3.D3 (Serotec, Oxford, UK) diluted 1:2000 with PBS. The following day plates were blocked with a 1% bovine serum albumin (Sigma, St Louis, MO, USA) solution in PBS for 2 h. Standards of full length sCR1 (gift from Professor D Fearon, Cambridge University) in the range 5 g/ml to 160 pg/ml, (lowest level of detection is 320 pg/ml) and samples were then loaded on washed plates and incubated for 3 h. Plates were again washed and sCR1 detected with a polyclonal rabbit antisera (gift from Dr R Smith, AdProtec, Royston, UK) diluted 1:2000 with PBS for 1 h. Second layer detection was performed with antirabbit Ig, horseradish-peroxidase linked F(ab) 2 fragment from donkey (Amersham, Buckingham, UK) which was diluted 1:2000 with PBS and incubated for 1 h. Signal was detected using the TMB microwell substrate system (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) and the reaction stopped by addition of 1 m phosphoric acid. Absorbance measurements were performed Gene Therapy at 450 nm using an EL 312e microplate biokinetics reader (Bio-Tek Instruments, CA, USA).
Quantitation of EGFP expression by cell fluorescence
Fluorescence was quantitated with cells fixed with PBS containing 2% paraformaldehyde by flow cytometry using FACScan II (Beckton Dickinson, Mount View, CA, USA), and fluorescence data were analysed using Cell Quest software.
Statistical methods
Descriptive statistics, correlation and Student's t test for two sample data of unequal variance were performed using Microsoft Excel 98 software.
